Valneva announced its positive results today vaccine against COVID-19 in the initial stages of clinical trials and plans to begin third-phase trials this month, according to APE.
THE French pharmaceutical industry, whose vaccine uses the technology of its approved Japanese encephalitis vaccine, has been tested its vaccine against COVID-19 in 153 adults with three dose levels based on a two-dose schedule, with vaccinations three weeks apart.
The Valneva shares up 8% at the start of trading.
The COVID-19 vaccine, Valneva adds, is “generally safe and well tolerated in all dose groups tested, with no safety concerns identified by the Independent Safety Data Monitoring Board.”
Valneva notes that the vaccine, for which the American company Dynavax provides an adjuvant, is also “extremely immunogenic”, with “more than 90% of all participants in the study” developing significant levels of antibodies to the new coronavirus protein spike.
“Based on the data evaluated, the company decided to promote the high dose in the third phase clinical trial,” according to Valneva.
Valneva has signed an agreement with Britain for up to 190 million installments by 2025 in a transaction with a potential value of up to 1.4 billion euros. The company is also in talks with the European Union to supply it with 60 million installments.
The company noted that it intends to apply for approval of its vaccine in Britain this fall and that talks with other regulators are ongoing.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
